Genentech 1Q Revenues: $3.1 billion (+8%) 1Q Earnings: $790 million (+12%) Comments: Rituxan sales were $605 million (+13%), Avastin sales were $600 million (+13%), and Herceptin sales were $339 million (+9%). 1Q08 Avastin U.S. sales include a net deferral of approximately $1 million related to the company’s Avastin Patient Assistance Program. R&D expenses were up 1% to $617 million, representing 20% of operating revenues. The company expects to submit a sBLA to the FDA for acceler...